trial

SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia

NCTId NCT00364429
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 55 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2005-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
55 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2005-07
Primary completion
2005-07
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
[123]I-CNS 1261LorazepamRisperidone

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
Barcelona, Spain

Facts & assertions

4 sourced
Enrollment
55
Phase
PHASE1
Primary Completion Date
2005-07
Status
TERMINATED
relationships
The graph out of here
drug
[123]I-CNS 1261
drug
Lorazepam
drug
Risperidone
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication